Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO phase 3 study of eneboparatide in chronic hypoparathyroidism
CTR20251439Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eneboparatide in chronic hypoparathyroidism, sponsored by Alexion Pharmaceuticals. Started Apr 2025; status: active.
02
Drugs
eneboparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on CTR20251439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251439.